Ofatumumab therapy – treatment optimization in patients with relapsing- -remitting multiple sclerosis Case report

Abstract

Optimization of therapy in patients with relapsing-remitting multiple sclerosis previously treated with immunomodulators requires an individual approach for each patient. Ofatumumab is a drug used in the treatment of patients with relapsing-remitting multiple sclerosis, classified as a highly effective therapy and at the same time a drug with a favorable safety profile. This article presents two patients who required a change in immunomodulatory therapy. In the first patient, partial ineffectiveness of the initial immunomodulatory therapy was observed during treatment. Ofatumumab was used in the patient as a highly effective therapy available in the first-line treatment of multiple sclerosis under the drug program of the Ministry of Health. In the second patient, ofatumumab was used as escalation therapy due to the occurrence of disease activity and side effects during the use of previous immunomodulatory drugs.